Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
11:27:43 EDT Mon 29 Apr 2024
Enter Symbol
or Name
USA
CA



News for U:KALV from 2023-04-30 to 2024-04-29 - 44 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2024-04-22 06:30U:KALVNews ReleaseKalVista Pharmaceuticals Appoints William C. Fairey to Board of Directors
2024-04-03 06:30U:KALVNews ReleaseKalVista Pharmaceuticals to Present at 23rd Annual Needham Virtual Healthcare Conference
2024-04-02 06:30U:KALVNews ReleaseKalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-03-18 06:30U:KALVNews ReleaseKalVista Pharmaceuticals Presents Real-World Data on Burden of Treatment and HAE Attack Journey at the 2024 HAEi Regional Conference Americas
2024-03-12 06:30U:KALVNews ReleaseKalVista Pharmaceuticals Awarded UK Promising Innovative Medicine (PIM) Designation for Sebetralstat
2024-03-11 06:30U:KALVNews ReleaseKalVista Pharmaceuticals Reports Third Fiscal Quarter Results and Provides Operational Update
2024-03-08 06:30U:KALVNews ReleaseKalVista Pharmaceuticals to Present HAE Attack Journey Data at 2024 HAEi Regional Conference Americas
2024-03-07 06:30U:KALVNews ReleaseKalVista Pharmaceuticals Announces Appointment of Benjamin L. Palleiko as Chief Executive Officer
2024-03-06 06:30U:KALVNews ReleaseKalVista Pharmaceuticals to Participate in the Leerink Partners 2024 Global Biopharma Conference
2024-03-04 06:30U:KALVNews ReleaseKalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-02-27 06:30U:KALVNews ReleaseKalVista Pharmaceuticals Presents Data on Unmet Needs in HAE from a Patient Perspective at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting
2024-02-26 06:30U:KALVNews ReleaseKalVista Pharmaceuticals Presents Additional Phase 3 KONFIDENT Data at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting
2024-02-20 06:30U:KALVNews ReleaseKalVista Pharmaceuticals Awarded UK Innovation Passport for Sebetralstat
2024-02-16 06:30U:KALVNews ReleaseKalVista Pharmaceuticals to Present Phase 3 Sebetralstat Data at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting
2024-02-15 06:30U:KALVNews ReleaseKalVista Pharmaceuticals Announces Pricing of a $160.1 Million Public Offering of Common Stock and Pre-Funded Warrants
2024-02-14 16:18U:KALVNews ReleaseKalVista Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
2024-02-13 06:30U:KALVNews ReleaseKalVista Pharmaceuticals Reports Phase 3 KONFIDENT Trial Meets All Endpoints for Sebetralstat as First Oral On-demand Therapy for Hereditary Angioedema
2024-02-02 06:30U:KALVNews ReleaseKalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-12-20 06:30U:KALVNews ReleaseKalVista Pharmaceuticals Announces Publication of First Oral Factor XIIa Data in Frontiers in Pharmacology
2023-12-07 06:30U:KALVNews ReleaseKalVista Pharmaceuticals Reports Second Fiscal Quarter Results and Provides Operational Update
2023-12-05 06:30U:KALVNews ReleaseKalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-11-14 06:30U:KALVNews ReleaseKalVista Pharmaceuticals Presents Real-World Data at the 2023 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology
2023-11-13 06:30U:KALVNews ReleaseKalVista Pharmaceuticals Announces Phase 3 KONFIDENT Trial Milestone Achieved
2023-11-07 06:30U:KALVNews ReleaseKalVista Pharmaceuticals to Present at Upcoming Investor Conferences
2023-11-03 06:30U:KALVNews ReleaseKalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-11-02 06:30U:KALVNews ReleaseKalVista Pharmaceuticals to Present Data at the 2023 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology
2023-10-24 06:30U:KALVNews ReleaseKalVista Pharmaceuticals Presents Data on HAE Attacks in Patients Receiving Long-Term Prophylaxis at the Asia Pacific Association of Allergy, Asthma and Clinical Immunology 2023 International Conference
2023-10-03 06:30U:KALVNews ReleaseKalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-09-19 06:30U:KALVNews ReleaseKalVista Pharmaceuticals to Present at Cantor Global Healthcare Conference
2023-09-07 06:30U:KALVNews ReleaseKalVista Pharmaceuticals Reports First Fiscal Quarter Results and Provides Operational Update
2023-08-28 06:30U:KALVNews ReleaseKalVista Pharmaceuticals to Present HAE Attack Journey Data at 2023 HAEi Regional Conference EMEA
2023-08-02 16:15U:KALVNews ReleaseKalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-07-25 06:30U:KALVNews ReleaseKalVista Pharmaceuticals Expands Senior Leadership Team with Appointment of Nicole Sweeny as Chief Commercial Officer
2023-07-24 06:30U:KALVNews ReleaseKalVista Pharmaceuticals Presents New HAE Attack Journey Data at 2023 US HAEA National Summit
2023-07-14 06:30U:KALVNews ReleaseKalVista Pharmaceuticals to Present HAE Attack Journey Data at 2023 US HAEA National Summit
2023-07-07 06:30U:KALVNews ReleaseKalVista Pharmaceuticals Provides Operational Update and Fiscal Year Financial Results
2023-07-05 06:30U:KALVNews ReleaseKalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-06-12 06:30U:KALVNews ReleaseKalVista Pharmaceuticals Presents New Data at 2023 Meeting of the European Academy of Allergy and Clinical Immunology
2023-06-05 06:30U:KALVNews ReleaseKalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-06-02 06:30U:KALVNews ReleaseKalVista Pharmaceuticals to Present Data at the 2023 Meeting of the European Academy of Allergy and Clinical Immunology (EAACI)
2023-05-31 06:30U:KALVNews ReleaseKalVista Pharmaceuticals to Present at Jefferies Global Healthcare Conference
2023-05-23 06:30U:KALVNews ReleaseKalVista Pharmaceuticals to Present at Stifel 2023 Tailoring Genes: Genetic Medicines Day Virtual Conference
2023-05-08 06:30U:KALVNews ReleaseKalVista Pharmaceuticals Presents Data at 13th C1-inhibitor Deficiency & Angioedema Workshop
2023-05-02 06:30U:KALVNews ReleaseKalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)